Effect of S-aspirin, a novel hydrogen-sulfide-releasing aspirin (ACS14), on atherosclerosis in apoE-deficient mice

European Journal of Pharmacology

Volumn 697, Issue 1-3, 2012, Pages 106-116

  Zhang, Huili ^a   Guo, Changfa ^b   Zhang, Alian ^a   Fan, Yuqi ^a   Gu, Ting ^a   Wu, Duojiao ^b   Sparatore, Anna ^c   Wang, Changqian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Atherosclerosis; CX3CR1; Hydrogen sulfide; Macrophage; Peroxisome proliferator activated receptor

Indexed keywords

2 ACETYLOXYBENZOIC ACID 4 (3 THIOXO 3H 1,2 DITHIOL 5 YL)PHENYL ESTER; 2 CHLORO 5 NITROBENZANILIDE; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; ACS 14; APOLIPOPROTEIN E; CHEMOKINE RECEPTOR CX3CR1; GAMMA INTERFERON; HYDROGEN SULFIDE; LIPOPOLYSACCHARIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BRACHIOCEPHALIC TRUNK; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; FAT INTAKE; INCUBATION TIME; MACROPHAGE ACTIVATION; MACROPHAGE MIGRATION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION;

ANIMALS; APOLIPOPROTEINS E; ASPIRIN; ATHEROSCLEROSIS; BRACHIOCEPHALIC TRUNK; CELL LINE; CHEMOTAXIS; DISEASE MODELS, ANIMAL; DISULFIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GASTRIC MUCOSA; HYDROGEN SULFIDE; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; INTERFERON-GAMMA; INTESTINAL MUCOSA; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; PPAR GAMMA; RECEPTORS, CHEMOKINE; TIME FACTORS;

EID: 84869494222     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.10.005     Document Type: Article

References (37)

1. J. Barlic, Y. Zhang, J.F. Foley, and P.M. Murphy Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor γ-dependent pathway Circulation 114 2006 807 819
2. J. Barlic, and P.M. Murphy An oxidized lipid-PPARγ-chemokine pathway in the regulation of macrophage: vascular smooth muscle cell adhesion Trends Cardiovasc. Med 17 2007 269 274
3. J.F. Bazan, K.B. Bacon, G. Hardiman, W. Wang, K. Soo, D. Rossi, D.R. Greaves, A. Zlotnik, and T.J. Schall A new class of membrane-bound chemokine with a CX3C motif Nature 385 1997 640 644
4. K. Chen., R. Nezu, M. Inoue, M. Wasa, Y. Liboshi, M. Fukuzawa, S. Kamata, Y. Takaqi, and A. Okada Beneficial effects of growth hormone combined with parenteral nutrition in the management of inflammatory bowel disease: an experimental study Surgery 121 1997 212 218
5. C. Combadiere, S. Potteaux, J.L. Gao, B. Esposito, S. Casanova, E.J. Lee, P. Debré, A. Tedqui, P.M. Murphy, and Z. Mallat Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice Circulation 107 2003 1009 1016
6. P. Dallaire, K. Bellmann, M. Laplante, S. Gélinas, C. Centeno-Baez, P. Penfornis, M.L. Peyot, M.G. Latour, J. Lamontagne, M.E. Trujillo, P.E. Scherer, M. Prentki, Y. Deshaies, and A. Marette Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated Receptor- γ agonism Diabetes 57 2008 1999 2011
7. 2S) Cell Biochem. Funct. 28 2010 95 106
8. J.A. Oates, A. Brash, and G. Fitzgerald Comparison of the effects of selective inhibition of thromboxane synthase with those of inhibition of the cyclooxygenase enzyme in man Trans. Am. Clin. Climatol. Assoc 95 1984 157 162
9. L.M. Gan, J. Grönros, U. Hägg, J. Wikström, C. Theodoropoulos, P. Friberg, and R. Fritsche-Danielson Non-invasive real-time imaging of atherosclerosis in mice using ultrasound biomicroscopy Atherosclerosis 190 2007 313 320
10. P. Gresele, and S. Momi Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders Cardiovasc. Drug Rev 24 2006 148 168
11. L.F. Hu, P.T. Wong, P.K. Moore, and J.S. Bian Hydrogen sulfide attenuates lipopolysaccharide-induced inflammation by inhibition of p38 mitogen-activated protein kinase in microglia J. Neurochem. 100 2007 1121 1128
12. J. Johnson, K. Carson, H. Williams, S. Karanam, A. Newby, G. Angelini, S. George, and C. Jackson Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment Circulation 111 2005 1422 1430
13. D.J. Lefer A new gaseous signaling molecule emerges: cardioprotective role of hydrogen sulfide Proc. Natl. Acad. Sci 104 2007 17907 17908
14. -/- mice reveals a role for fractalkine in atherogenesis J. Clin. Invest. 111 2003 333 340
15. 2S) - the third gas of interest for pharmacologists Pharmacol. Rep 59 2007 4 24
16. A.D. Lucas, C. Bursill, T.J. Guzik, J. Sadowski, K.M. Channon, and D.R. Greaves Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1) Circulation 108 2003 2498 2504
17. D.H. McDermott, J.P. Halcox, W.H. Schenke, M.A. Waclawiw, M.N. Merrell, N. Epstein, A.A. Quyyumi, and P.M. Murphy Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis Circ. Res. 89 2001 401 407
18. D. Moatti, S. Faure, F. Fumeron, Mel-W. Amara, P. Seknadji, D.H. McDermott, P. Debré, M.C. Aumont, P.M. Murphy, D. de Prost, and C. Combadière Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease Blood 97 2001 1925 1928
19. P.K. Moore, M. Bhatia, and S,M. Moochhala Hydrogen sulfide: from the smell of the past to the mediator of the future? Trends Pharmacol Sci 24 2003 609 611
20. A. Niessner, R. Marculescu, A. Haschemi, G. Endler, G. Zorn, C.M. Weyand, G. Maurer, C. Mannhalter, J. Wojta, O. Wagner, and K. Huber Opposite effects of CX3CR1 receptor polymorphisms V249I and T280M on the development of acute coronary syndrome. A possible implication of fractalkine in inflammatory activation Thromb. Haemost. 93 2005 949 954
21. G.D. Norata, K. Garlaschelli, M. Ongari, S. Raselli, L. Grigore, and A.L. Catapano Effects of fractalkine receptor variants on common carotid artery intima-media thickness Stroke 37 2006 1558 1561
22. G.S. Oh, H.O. Pae, B.S. Lee, B.N. Kim, J.M. Kim, H.R. Kim, and S.B. Jeon Hydrogen sulfide inhibits nitric oxide production and nuclear factor-κB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide Free Radic. Biol. Med. 41 2006 106 119
23. G. Rossoni, B. Manfredi, V. Tazzari, A. Sparatore, S. Trivulzio, P. Del Soldato, and F. Berti Activity of a new hydrogen sulfide-releasing aspirin (ACS14) on pathological cardiovascular alterations induced by glutathione depletion in rats Eur. J. Pharmacol. 648 2010 139 145
24. A. Shibuya, K. Wada, A. Nakajima, M. Saeki, K. Katayama, T. Mayumi, T. Kadowaki, H. Niwa, and Y. Kamisaki Nitration of PPARγ inhibits ligand-dependent translocation into the nucleus in a macrophage-like cell line, RAW 264 FEBS Lett 525 2002 43 47
25. 2S-releasing aspirin Free Radic. Biol. Med. 46 2009 586 592
26. I.N. Staikov, M. Arnold, H.P. Mattle, L. Remondal, M. Sturzenegger, R.W. Baumgartner, and G. Schroth Comparison of the ECST, CC, and NASCET grading methods and ultrasound for assessing carotid stenosis. European Carotid Surgery Trial. North American Symptomatic Carotid Endarterectomy Trial J. Neurol. 247 2000 681 686
27. T. Stroff, S. Plate, J.S. Ebrahim, K.H. Ehrlich, M. Respondek, and B.M. Peskar Tachykinin-induced increase in gastric mucosal resistance: role of primary afferent neurons, CGRP and NO Am. J. Physiol. 271 1996 G1017 G1027
28. C. Tang, X. Li, and J. Du Hydrogen sulfide as a new endogenous gaseous transmitter in the cardiovascular system Curr. Vasc. Pharmacol. 4 2006 17 22
29. J.L. Wallace, G. Caliendo, V. Santagada, G. Cirino, and S. Fiorucci Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat Gastroenterology 132 2007 261 271
30. Y. Wan, and R.M. Evans Rosiglitazone activation of PPARγ suppresses fractalkine signaling J. Mol. Endocrinol. 44 2010 135 142
31. 2S be the third endogenous gaseous transmitter? FASEB J 16 2002 1792 1798
32. Y. Wang, X. Zhao, H. Jin, H. Wei, W. Li, D. Bu, X. Tang, Y. Ren, C. Tang, and J. Du Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice Arterioscler. Thromb. Vasc. Biol. 29 2009 173 179
33. M. Whiteman, J.S. Armstrong, S.H. Chu, S. Jia-Ling, B.S. Wong, N.S. Cheung, B. Halliwell, and P.K. Moore The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite 'scavenger'? J. Neurochem 90 2004 765 768
34. M. Whiteman, L. Li, I. Kostetski, S.H. Chu, J.L. Siau, M. Bhatia, and P.K. Moore Evidence for the formation of a novel nitrosothiol from the gaseous mediators nitric oxide and hydrogen sulphide Biochem. Biophys. Res. Commun. 343 2006 303 310
35. B.W. Wong, D. Wong, and B.M. McManus Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease Cardiovasc. Pathol. 11 2002 332 338
36. D.J. Wu, J.Z. Xu, Y.J. Wu, L Jean-Charles, B Xiao, P.J. Gao, and D.L. Zhu Effects of fasudil on early atherosclerotic plaque formation and established lesion progression in apolipoprotein E-knockout mice Atherosclerosis 207 2009 68 73
37. Z.Z. Zhao, Z. Wang, G.H. Li, R. Wang, J.M. Tan, X. Cao, R. Sou, and Z.S. Jiang Hydrogen sulfide inhibits macrophage-derived foam cell formation Exp. Biol. Med. (Maywood) 236 2011 169 176